You are here
ACO Safeguards Needed to Ensure Patient Access to Breakthrough Technologies
WASHINGTON, D.C. – Stephen J. Ubl, president and CEO of the Advanced Medical Technology Association (AdvaMed), released the following statement in response to today’s Senate Finance Committee hearing on “Delivery System Reform: Progress Report from CMS”:
“AdvaMed supports the overall goals of the new payment modalities included in the Affordable Care Act and believes such reforms could improve the quality and efficiency of health care delivery, as well as improve the coordination of care for the chronically ill. However, implementation of these delivery reforms is threatening to deny or delay patient access to innovative medical technologies that are more appropriate for treating their medical conditions.
“Implementation, testing and evaluation of these new payment modalities under the Affordable Care Act must be guided by a commitment to ensuring patients have access to the most appropriate care and medical technologies.
“A failure to reflect new treatments and appropriately account for them in the design of these new delivery models could have a chilling effect on medical progress, and could discourage early adoption of new treatments that provide improved outcomes for patients.
“In order to protect medical progress and patient access to treatments and diagnostics, AdvaMed urges CMS to incorporate in both the ACO and bundled payment programs adjustments for qualifying innovative technologies, as well as safeguards to protect beneficiary and physician choice when selecting the most appropriate treatments, including innovative technologies.”
# # #
AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies.